Enabling consistency in pluripotent stem Cell-Derived products for research and development and clinical applications through material standards

Stem Cells Translational Medicine

Volumn 4, Issue 3, 2015, Pages 217-223

  French, Anna ^a   Bravery, Christopher ^d   Smith, James ^a   Chandra, Amit ^e   Archibald, Peter ^e   Gold, Joseph D ^f   Artzi, Natalie ^h   Kim, Hae Won ⁱ   Barker, Richard W ^a   Meissner, Alexander ^k,l,m   Wu, Joseph C ^f,g   Knowles, Jonathan C ^j,n   Williams, David ^e   García Cardeña, Guillermo ^l,q,s   Sipp, Doug ^t   Oh, Steve ^u   Loring, Jeanne F ^v   Rao, Mahendra S ^w   Reeve, Brock ^k   Wall, Ivan ^a,j,o   Carr, Andrew J ^a,b,x   Bure, Kim ^x   Stacey, Glyn ^y   Karp, Jeffrey M ^k,r,z   Snyder, Evan Y ^aa,ab,ac   Brindley, David A ^a,c,k,m,p,ad   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Consulting on Advanced Biologicals Ltd ^*  (United Kingdom)

^e LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^f STANFORD UNIVERSITY   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h USA   (United States)

ⁱ Wonkwang Biomaterial Implant Research Institute   (South Korea)

^j Dankook University   (South Korea)

^k HARVARD STEM CELL INSTITUTE   (United States)

^l BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^m Harvard University   (United States)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p UNIVERSITY OF LONDON   (United Kingdom)

^q Laboratory for Systems Biology   (United States)

^r BRIGHAM AND WOMEN S HOSPITAL   (United States)

^s HARVARD MEDICAL SCHOOL   (United States)

^t RIKEN Center for Biosystems Dynamics Research   (Japan)

^u AGENCY FOR SCIENCE   (Singapore)

^v SCRIPPS RESEARCH INSTITUTE   (United States)

^w NATIONAL INSTITUTES OF HEALTH   (United States)

^x SARTORIUS STEDIM BIOTECH GMBH   (Germany)

^y NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^z MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^aa BURNHAM INSTITUTE   (United States)

^ab UNIVERSITY OF CALIFORNIA   (United States)

^ac SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^ad USCF Stanford Center of Excellence in Regulatory Science and Innovation (CERSI)   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY AGENT;

ARTICLE; BIOASSAY; CELL THERAPY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG SCREENING; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HUMAN; INTERNAL CONSISTENCY; NERVE CELL; NONHUMAN; PLURIPOTENT STEM CELL; REPRODUCIBILITY; SAFETY; SCIENTIST; STANDARD; TRANSLATIONAL RESEARCH; DEVICES; ECONOMICS; MEDICAL RESEARCH; PRECLINICAL STUDY; PROCEDURES; STANDARDS; TRENDS;

BIOMEDICAL RESEARCH; DRUG EVALUATION, PRECLINICAL; HUMANS; PLURIPOTENT STEM CELLS; REFERENCE STANDARDS;

EID: 84923406920     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0233     Document Type: Article

References (34)

1. Allen RH, Sriram RD. The role of standards in innovation. Technol Forecast Soc Change 2000;64:171-181.
2. Sheridan B, Stacey G, Wilson A et al. Standards can help bring cell therapy products to market. Bioprocess Int 2012;10:18-21.
3. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012;483:531-533.
4. Global Biological Standards Institute. The Case for Standards in Life Science Research: Seizing Opportunities at a Time of Critical Need.Washington, DC:GlobalBiological Standards Institute,2013.
5. Grskovic M, Javaherian A, Strulovici B et al. Induced pluripotent stem cells— Opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011; 10:915-929.
6. Merkle FT, Eggan K. Modelinghumandisease with pluripotent stem cells: From genome association to function. Cell Stem Cell 2013;12:656-668.
7. Engle SJ, Puppala D. Integrating human pluripotent stem cells into drug development. Cell Stem Cell 2013;12:669-677.
8. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012; 379:713-720.
9. Alper J. Gerongetsgreenlight forhumantrial of ES cell-derived product. Nat Biotechnol 2009; 27:213-214.
10. Stacey GN, Crook JM, Hei D et al. Banking human induced pluripotent stem cells: Lessons learned from embryonic stem cells? Cell Stem Cell 2013;13:385-388.
11. Turner M, Leslie S, Martin NG et al.Toward the development of a global induced pluripotent stemcell library.Cell StemCell 2013;13:382-384.
12. Maherali N,Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;3:595-605.
13. International Stem Cell Banking Initiative. Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev 2009;5:301-314.
14. Loring JF, Rao MS. Establishing standards for the characterization of human embryonic stem cell lines. STEM CELLS 2006;24:145-150.
15. Amps K, Andrews PW, Anyfantis G et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011;29:1132-1144.
16. International Stem Cell Initiative, Akopian V, Andrews PW et al. Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells. In Vitro Cell Dev Biol Anim 2010;46:247-258.
17. Enver T, Soneji S, Joshi C et al. Cellular differentiation hierarchies in normal and cultureadapted human embryonic stem cells. Hum Mol Genet 2005;14:3129-3140.
18. Geron. Geron to ProceedWith FirstHuman Clinical Trial for Embryonic Stem Cell-Based Therapy. 2010. Available at http://ir.geron.com?phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1636138. Accessed September 20, 2014.
19. Narsinh KH, Sun N, Sanchez-Freire V et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest 2011;121:1217-1221.
20. Armbruster D, Miller RR. The Joint Committee for Traceability in Laboratory Medicine (JCTLM): A global approach to promote the standardisation of clinical laboratory test results. Clin Biochem Rev 2007;28: 105-113.
21. European Union. Commission directive 2009/120/EC of 14 September 2009. Official Journal of the European Union, 2009.
22. Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. Centre for Biologics Evaluation and Research, 2011.
23. World Health Organization. Forty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations. WHO Technical Report Series 957, 2010.
24. Bravery CA, French A. Reference materials for cellular therapeutics. Cytotherapy 2014; 16:1187-1196.
25. National Institute for Biological Standards and Control. Working standard FITC untouched CD41 cells (SS-222). Available at http://www.nibsc.org/CFAR%20Datasheets/5027.pdf. Accessed October 9, 2014.
26. Chen A, Ting S, Seow J et al. Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells. Stem Cell Res Ther 2014;5:12.
27. Adewumi O, Aflatoonian B, Ahrlund-Richter L et al. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007; 25:803-816.
28. Josephson R, Ording CJ, Liu Y et al. Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. STEM CELLS 2007;25:437-446.
29. Murphy CL, Polak JM.Differentiatingembryonic stem cells: GAPDH, but neither HPRT nor betatubulin is suitable as an internal standard for measuringRNAlevels. TissueEng2002;8:551-559.
30. Zhai Z, Yao Y, Wang Y. Importance of suitable reference gene selection for quantitative RT-PCR during ATDC5 cells chondrocyte differentiation. PLoS One 2013;8:e64786.
31. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622.
32. Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME)—Toward standards for microarray data. Nat Genet 2001;29:365-371.
33. Müller FJ, Schuldt BM, Williams R et al. A bioinformatic assay for pluripotency in human cells. Nat Methods 2011;8:315-317.
34. Bock C, Kiskinis E, Verstappen G et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011;144: 439-452.